|
1
|
Sakaguchi S: Naturally arising
Foxp3-expressing CD25+CD4+ regulatory T cells
in immunological tolerance to self and non-self. Nat Immunol.
6:345–352. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fontenot JD, Gavin MA and Rudensky AY:
Foxp3 programs the development and function of
CD4+CD25+ regulatory T cells. Nat Immunol.
4:330–336. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wan YY and Flavell RA: Regulatory T-cell
functions are subverted and converted owing to attenuated Foxp3
expression. Nature. 445:766–770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huber S and Schramm C: TGF-β and
CD4+CD25+ regulatory T cells. Front Biosci.
11:1014–1023. 2006.
|
|
5
|
Fantini MC, Becker C, Monteleone G, et al:
Cutting edge: TGF-β induces a regulatory phenotype in
CD4+CD25+ T cells through Foxp3 induction and
down-regulation of Smad7. J Immunol. 172:5149–5153. 2004.
|
|
6
|
Chen W, Jin W, Hardegen N, et al:
Conversion of peripheral CD4+CD25− naive T
cells to CD4+CD25+ regulatory T cells by
TGF-β induction of transcription factor Foxp3. J Exp Med.
198:1875–1886. 2003.
|
|
7
|
Liu VC, Wong LY, Jang T, et al: Tumor
evasion of the immune system by converting
CD4+CD25− T cells into
CD4+CD25+ T regulatory cells: role of
tumor-derived TGF-β. J Immunol. 178:2883–2892. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang S, Alard P, Zhao Y, et al:
Conversion of CD4+CD25− cells into
CD4+CD25+ regulatory T cells in vivo requires
B7 costimulation, but not the thymus. J Exp Med. 201:127–137.
2005.
|
|
9
|
Knoechel B, Lohr J, Kahn E, et al:
Sequential development of interleukin 2-dependent effector and
regulatory T cells in response to endogenous systemic antigen. J
Exp Med. 202:1375–1386. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maynard CL, Harrington LE, Janowski KM, et
al: Regulatory T cells expressing interleukin 10 develop from
Foxp3+ and Foxp3− precursor cells in the
absence of interleukin 10. Nat Immunol. 8:931–941. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng SG, Wang J, Wang P, et al: IL-2 is
essential for TGF-β to convert naive
CD4+CD25− cells to
CD25+Foxp3+ regulatory T cells and for
expansion of these cells. J Immunol. 178:2018–2027. 2007.
|
|
12
|
Polansky JK, Kretschmer K, Freyer J, et
al: DNA methylation controls Foxp3 gene expression. Eur J Immunol.
38:1654–1663. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shull MM, Ormsby I, Kier AB, et al:
Targeted disruption of the mouse transforming growth factor-β 1
gene results in multifocal inflammatory disease. Nature.
359:693–699. 1992.
|
|
14
|
Kulkarni AB, Huh CG, Becker D, et al:
Transforming growth factor β1 null mutation in mice causes
excessive inflammatory response and early death. Proc Natl Acad Sci
USA. 90:770–774. 1993.
|
|
15
|
Lucas PJ, Kim SJ, Melby SJ, et al:
Disruption of T cell homeostasis in mice expressing a T
cell-specific dominant negative transforming growth factor β II
receptor. J Exp Med. 191:1187–1196. 2000.PubMed/NCBI
|
|
16
|
Gorelik L and Flavell RA: Abrogation of
TGF β signaling in T cells leads to spontaneous T cell
differentiation and autoimmune disease. Immunity. 12:171–181.
2000.
|
|
17
|
Li MO, Sanjabi S and Flavell RA:
Transforming growth factor-β controls development, homeostasis, and
tolerance of T cells by regulatory T cell-dependent and
-independent mechanisms. Immunity. 25:455–471. 2006.
|
|
18
|
Huber S, Schramm C, Lehr HA, et al:
Cutting edge: TGF-β signaling is required for the in vivo expansion
and immunosuppressive capacity of regulatory
CD4+CD25+ T cells. J Immunol. 173:6526–6531.
2004.
|
|
19
|
Marie JC, Letterio JJ, Gavin M, et al:
TGF-β1 maintains suppressor function and Foxp3 expression in
CD4+CD25+ regulatory T cells. J Exp Med.
201:1061–1067. 2005.
|
|
20
|
Saita N, Goto E, Yamamoto T, et al:
Association of galectin-9 with eosinophil apoptosis. Int Arch
Allergy Immunol. 128:42–50. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kageshita T, Kashio Y and Yamauchi A:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wada J, Ota K, Kumar A, et al:
Developmental regulation, expression, and apoptotic potential of
galectin-9, a β-galactoside binding lectin. J Clin Invest.
99:2452–2461. 1997.PubMed/NCBI
|
|
23
|
Matsumoto R, Matsumoto H, Seki M, et al: A
variant of human galectin-9, is a novel eosinophil chemoattractant
produced by T lymphocytes. J Biol Chem. 273:16976–16984. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kashio Y, Nakamura K and Abedin MJ:
Galectin-9 induces apoptosis through the calcium-calpain-caspase-1
pathway. J Immunol. 170:3631–3636. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu C, Anderson AC, Schubart A, et al: The
Tim-3 ligand galectin-9 negatively regulates T helper type 1
immunity. Nat Immunol. 6:1245–1252. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsuboi Y, Abe H, Nakagawa R, et al:
Galectin-9 protects mice from the Shwartzman reaction by attracting
prostaglandin E2-producing polymorphonuclear leukocytes. Clin
Immunol. 124:221–233. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fukushima, Tamaki S and Fukuda K: Roles of
galectin-9 in the development of experimental allergic
conjunctivitis in mice. Int Arch Allergy Immunol. 146:36–43. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seki M, Oomizu S, Sakata K, et al:
Galectin-9 suppresses the generation of Th17, promotes the
induction of regulatory T cells, and regulates experimental
autoimmune arthritis. Clin Immunol. 127:78–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sharvan S, Amol S, Hirashima M, et al:
Role of Tim-3/galectin-9 inhibitory interaction in viral-induced
immunopathology: shifting the balance toward regulators. J Immunol.
182:3191–3201. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lv K, Xu W, Wang CN, et al: Galectin-9
administration ameliorates CVB3 induced myocarditis by promoting
the proliferation of regulatory T cells and alternatively activated
Th2 cells. Clin Immunol. 140:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Coombes JL, Siddiqui KR, Arancibia-Carcamo
CV, et al: A functionally specialized population of mucosal
CD103+ DCs induces Foxp3+ regulatory T cells
via a TGF-β and retinoic acid-dependent mechanism. J Exp Med.
204:1757–1764. 2007.PubMed/NCBI
|
|
33
|
Valzasina B, Piconese S, Guiducci C, et
al: Tumor-induced expansion of regulatory T cells by conversion of
CD4+CD25− lymphocytes is thymus and
proliferation independent. Cancer Res. 66:4488–4495. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fantini MC, Becker C, Tubbe I, et al:
Transforming growth factor β induced Foxp3+ regulatory T
cells suppress Th1 mediated experimental colitis. Gut. 55:671–680.
2006.
|
|
35
|
Massague J: How cells read TGF-beta
signals. Nat Rev Mol Cell Biol. 1:169–178. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Massague J: TGF-beta signal transduction.
Annu Rev Biochem. 67:753–791. 1998. View Article : Google Scholar
|
|
37
|
Massague J and Chen YG: Controlling
TGF-beta signaling. Genes Dev. 14:627–644. 1998.
|
|
38
|
Massague J and Wotton D: Transcriptional
control by the TGF-beta/Smad signaling system. EMBO J.
19:1745–1754. 2000. View Article : Google Scholar : PubMed/NCBI
|
